Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, August 19, 2025

Mind the ‘Brain Age Gap’: A Meaningful Mediator of Cognitive Decline

 

Do you really think your competent? doctor has enough functioning brain cells to implement this and create EXACT PROTOCOLS to prevent cognitive decline post stroke? I don't.

Mind the ‘Brain Age Gap’: A Meaningful Mediator of Cognitive Decline

The gap between a brain’s chronological age and its predicted age on brain imaging appears to be a strong mediator of risk factors for cognitive decline, especially in individuals with cerebrovascular disease (CeVD), new research suggested.

In a cross-sectional study of more than 2000 participants, researchers used machine learning and brain scans to create a prediction model. An individual’s “brain age gap” (BAG) was then determined by subtracting the chronological brain age from the predicted brain age.

Results showed that a higher number of cognitive impairment risk factors were associated with lower cognitive performance scores — and that a larger BAG may influence this relationship, with the strongest effects observed in participants with CeVD.

In individuals with more markers of CeVD, such as microbleeds and infarcts, the BAG significantly influenced the link between cognitive impairment risk factors and overall cognitive function — particularly affecting executive function and language abilities.

“This suggests that accelerated brain aging, as measured by BAG, plays a disproportionate role in cognitive vulnerability among individuals with vascular pathology,” study co-investigator Saima Hilal, MD, PhD, assistant professor at the National University of Singapore, Singapore, told Medscape Medical News.

“While we expected BAG to have some mediating effect, the domain-specific nature of this influence was unexpected,” Hilal added.

The findings were published online on June 18 in Neurology.

Knowledge Gap

The investigators initiated the study to explore how the BAG neuroimaging-derived biomarker might help explain a connection between known risk factors for cognitive impairment and actual cognitive decline, particularly in Southeast Asian populations, Hilal reported.

“Prior research has largely focused on Western cohorts, leaving a gap in understanding how [CeVD], which is highly prevalent in Asia, may interact with BAG to affect cognition,” she said.

Additionally, she noted that CeVD often coexists with Alzheimer’s pathology in individuals from Southeast Asia. Understanding whether BAG could serve as a mediator in that relationship “could enhance early risk stratification and open new avenues for targeted cognitive interventions in at-risk populations,” Hilal said.

The researchers reviewed medical records for more than 2000 participants (mean age, 66 years; 53% men; 60% with no cognitive impairment) from the Singapore community and memory clinics to identify cognitive impairment risk factors.

For this, they used the Cognitive Impairment Scoring System (CISS), which consisted of 11 sociodemographic and vascular factors, including age, education, smoking status, blood pressure, and history of diabetes.

The investigators also measured cognitive performance using tests that assessed overall global cognition, executive function, language, memory, attention, visuomotor speed — which is the ability to coordinate visual information with motor actions — and visuoconstruction, which involves coordinating fine motor skills with spatial abilities.

Within the study population, 1437 did not have dementia and 646 served as the matched control group. All individuals had undergone structural MRIs.

CeVD burden was determined using markers associated with small and large vessel disease and cognitive dysfunction, including lacunar and cortical infarcts, cerebral microbleeds, and white matter hyperintensities.

‘Meaningful Biomarker’

Results showed a significant association between a higher CISS score (showing more impairment risk factors) and lower performance across all cognitive domains measured, especially visuomotor speed (β = -2.7; P < .001) and visuoconstruction (β = -3.0; P < .001). 

In the full patient population, BAG significantly influenced the relationship between CISS score and global cognition (proportion mediated, 9%; P < .05), especially the domains of language (18%; P = .001) and visuoconstruction (10%; P = .008).

The effect was even stronger for those with high CeVD burden. In this group, the association between CISS score and overall global cognition was significantly mediated by BAG (20%; P = .01), as were executive function (34%; P = .03) and language abilities (27%; P = .008).

There were no significant effects in the low-CeVD-burden group.

“These findings underscore the importance of stratifying by vascular burden and considering domain-specific outcomes when investigating brain aging,” Hilal said.

“For clinicians, the key message is that the brain age gap can serve as a meaningful intermediate biomarker linking modifiable risk factors to cognitive decline,” she added.

The investigators noted, however, that the study’s focus on a Southeast Asian population only could limit the generalizability of the findings.

“Future longitudinal studies should verify these relationships and explore additional factors not captured in our model,” they wrote.

The study was funded by the National University of Singapore, the National Medical Research Council Singapore, and the Singapore Ministry of Education. The investigators reported having no relevant financial relationships.

No comments:

Post a Comment